RT Journal Article
SR Electronic
T1 European drug market entries 2015 with new mechanisms of action
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 475
OP 480
DO 10.7861/clinmedicine.16-5-475
VO 16
IS 5
A1 Titus W P van den Heuvel
A1 Adam F Cohen
A1 Robert Rissmann
YR 2016
UL http://www.rcpjournals.org/content/16/5/475.abstract
AB In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma.